Shots:

• The companies will collaborate to develop- manufacture- and distribute AT-527 to combat COVID-19. If approved- Atea will be responsible for distributing the treatment option in the US- with the option to request Genentech’s support- and Roche will be responsible for distribution outside the US
• The therapy is currently being evaluated in P-II study for hospitalized patients with moderate COVID-19 with anticipated P-III initiation in Q1’21- that explores the potential use in patients outside of the hospital setting. Additionally- AT-527 may be developed for post-exposure prophylactic settings
• AT-527 is an investigational- oral- purine nucleotide prodrug that has demonstrated in antiviral activity against several enveloped single-stranded RNA virus- including human flavivirus and coronavirus

 ­ Ref: Roche | Image: Roche